Northern Trust’s Crescent Biopharma CBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.5M | Buy |
138,778
+121,549
| +705% | +$2.37M | ﹤0.01% | 3004 |
|
|
2026
Q1 | $316K | Hold |
17,229
| – | – | ﹤0.01% | 3784 |
|
|
2025
Q4 | $204K | Buy |
17,229
+413
| +2% | +$5.26K | ﹤0.01% | 3984 |
|
|
2025
Q3 | $200K | Buy |
+16,816
| New | +$223K | ﹤0.01% | 3983 |
|
|
2025
Q2 | – | Sell |
-1,170
| Closed | -$24.6K | – | 4441 |
|
|
2025
Q1 | $24.6K | Hold |
1,170
| – | – | ﹤0.01% | 4319 |
|
|
2024
Q4 | $29.1K | Hold |
1,170
| – | – | ﹤0.01% | 4338 |
|
|
2024
Q3 | $19.8K | Sell |
1,170
-108
| -8% | -$2.27K | ﹤0.01% | 4336 |
|
|
2024
Q2 | $36K | Sell |
1,278
-10
| -0.8% | -$1.04K | ﹤0.01% | 4263 |
|
|
2024
Q1 | $386K | Buy |
1,288
+175
| +16% | +$52.3K | ﹤0.01% | 3648 |
|
|
2023
Q4 | $263K | Buy |
1,113
+51
| +5% | +$7.93K | ﹤0.01% | 3783 |
|
|
2023
Q3 | $159K | Sell |
1,062
-147
| -12% | -$23.2K | ﹤0.01% | 3892 |
|
|
2023
Q2 | $210K | Buy |
1,209
+182
| +18% | +$30.5K | ﹤0.01% | 3813 |
|
|
2023
Q1 | $129K | Buy |
1,027
+50
| +5% | +$11.3K | ﹤0.01% | 4014 |
|
|
2022
Q4 | $296K | Sell |
977
-1
| -0.1% | -$147 | ﹤0.01% | 3689 |
|
|
2022
Q3 | $54K | Hold |
978
| – | – | ﹤0.01% | 4306 |
|
|
2022
Q2 | $58K | Hold |
978
| – | – | ﹤0.01% | 4366 |
|
|
2022
Q1 | $111K | Sell |
978
-7
| -0.7% | -$821 | ﹤0.01% | 4312 |
|
|
2021
Q4 | $142K | Buy |
985
+6
| +0.6% | +$1.09K | ﹤0.01% | 4313 |
|
|
2021
Q3 | $214K | Sell |
979
-108
| -10% | -$22.9K | ﹤0.01% | 4144 |
|
|
2021
Q2 | $252K | Sell |
1,087
-2,771
| -72% | -$705K | ﹤0.01% | 4055 |
|
|
2021
Q1 | $1.16M | Sell |
3,858
-466
| -11% | -$167K | ﹤0.01% | 3519 |
|
|
2020
Q4 | $1.63M | Sell |
4,324
-167
| -4% | -$58.5K | ﹤0.01% | 3289 |
|
|
2020
Q3 | $1.38M | Buy |
4,491
+81
| +2% | +$31K | ﹤0.01% | 3237 |
|
|
2020
Q2 | $1.66M | Sell |
4,410
-30
| -0.7% | -$8.49K | ﹤0.01% | 3136 |
|
|
2020
Q1 | $1.01M | Buy |
4,440
+116
| +3% | +$44.3K | ﹤0.01% | 3213 |
|
|
2019
Q4 | $2.29M | Sell |
4,324
-106
| -2% | -$57.4K | ﹤0.01% | 3036 |
|
|
2019
Q3 | $1.91M | Sell |
4,430
-246
| -5% | -$158K | ﹤0.01% | 3127 |
|
|
2019
Q2 | $5.57M | Buy |
4,676
+82
| +2% | +$98.1K | ﹤0.01% | 2504 |
|
|
2019
Q1 | $5.72M | Buy |
4,594
+172
| +4% | +$197K | ﹤0.01% | 2483 |
|
|
2018
Q4 | $4.19M | Sell |
4,422
-57
| -1% | -$68.6K | ﹤0.01% | 2615 |
|
|
2018
Q3 | $6.45M | Buy |
4,479
+318
| +8% | +$481K | ﹤0.01% | 2539 |
|
|
2018
Q2 | $6.71M | Buy |
4,161
+3,316
| +392% | +$5.7M | ﹤0.01% | 2520 |
|
|
2018
Q1 | $1.37M | Buy |
845
+149
| +21% | +$310K | ﹤0.01% | 3278 |
|
|
2017
Q4 | $1.17M | Buy |
696
+193
| +38% | +$255K | ﹤0.01% | 3360 |
|
|
2017
Q3 | $703K | Buy |
503
+45
| +10% | +$52.8K | ﹤0.01% | 3516 |
|
|
2017
Q2 | $510K | Sell |
458
-734
| -62% | -$606K | ﹤0.01% | 3583 |
|
|
2017
Q1 | $648K | Buy |
1,192
+78
| +7% | +$47.9K | ﹤0.01% | 3473 |
|
|
2016
Q4 | $680K | Buy |
1,114
+28
| +3% | +$17.5K | ﹤0.01% | 3451 |
|
|
2016
Q3 | $777K | Sell |
1,086
-3
| -0.3% | -$2.29K | ﹤0.01% | 3414 |
|
|
2016
Q2 | $792K | Buy |
1,089
+981
| +908% | +$676K | ﹤0.01% | 3413 |
|
|
2016
Q1 | $65K | Hold |
108
| – | – | ﹤0.01% | 3981 |
|
|
2015
Q4 | $62K | Hold |
108
| – | – | ﹤0.01% | 4024 |
|
|
2015
Q3 | $61K | Buy |
108
+7
| +7% | +$5.05K | ﹤0.01% | 4026 |
|
|
2015
Q2 | $80K | Sell |
101
-20
| -17% | -$16.5K | ﹤0.01% | 3985 |
|
|
2015
Q1 | $101K | Buy |
121
+14
| +13% | +$10.9K | ﹤0.01% | 4034 |
|
|
2014
Q4 | $77K | Hold |
107
| – | – | ﹤0.01% | 4025 |
|
|
2014
Q3 | $74K | Sell |
107
-619
| -85% | -$501K | ﹤0.01% | 4082 |
|
|
2014
Q2 | $612K | Buy |
726
+434
| +149% | +$432K | ﹤0.01% | 3545 |
|
|
2014
Q1 | $477K | Buy |
+292
| New | +$353K | ﹤0.01% | 3552 |
|
Other funds holding CBIO
FFM
LGM
FIS
BCM
NCM
Northern Trust's CBIO Position: Q2 2026 in Review
Northern Trust increased its Crescent Biopharma (CBIO) stake by 705% in Q2 2026, buying an estimated $2.37M and bringing the position to 138,778 shares worth $2.5M. The position accounts for ﹤0.01% of the portfolio, ranked #3004.
Northern Trust first reported a position in CBIO in Q1 2014 and has held it in 49 quarters since. The position peaked at $6.71M in Q2 2018. 70 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.
- Northern Trust held 138,778 shares of Crescent Biopharma worth $2.5M as of Q2 2026.
- Northern Trust bought 121,549 Crescent Biopharma shares in Q2 2026, an estimated $2.37M.
- Crescent Biopharma made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #3004 holding.
- Northern Trust first reported a position in Crescent Biopharma in Q1 2014 and has held it in 49 quarters since.
- Northern Trust's Crescent Biopharma position peaked at $6.71M in Q2 2018.
- 70 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.
Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.